Polyphyllin VII Promotes Apoptosis in Breast Cancer by Inhibiting MAPK/ERK Signaling Pathway through Downregulation of SOS1. 2024

Shu-Guang Du, and Hua-Min Zhang, and Yun-Xia Ji, and Yu-Lin Tian, and Dan Wang, and Kun Zhu, and Qing-Gao Zhang, and Shuang-Ping Liu
Chronic Disease Research Center, Medical College, Dalian University, Xuefu Road 10, Dalian 116622, P. R. China.

Polyphyllin VII is a biologically active herbal monomer extracted from the traditional Chinese herbal medicine Chonglou. Many studies have demonstrated the anticancer activity of polyphyllin VII against various types of cancers, such as colon, liver, and lung cancer, but its effect on breast cancer has not been elucidated. In this study, we demonstrate that polyphyllin VII inhibited proliferation, increased production of intracellular reactive oxygen species, and decreased mitochondrial membrane potential in breast cancer cells. Notably, polyphyllin VII also induced apoptosis via the mitochondrial pathway. Transcriptome sequencing was used to analyze the targets of PPVII in regulating breast cancer cells. Mechanistic studies showed that polyphyllin VII downregulated Son of Sevenless1 (SOS1) and inhibited the MAPK/ERK pathway. Furthermore, PPVII exerted strong antitumor effects in vivo in nude mice injected with breast cancer cells. Our results suggest that PPVII may promote apoptosis through regulating the SOS1/MAPK/ERK pathway, making it a possible candidate target for the treatment of breast cancer.

UI MeSH Term Description Entries

Related Publications

Shu-Guang Du, and Hua-Min Zhang, and Yun-Xia Ji, and Yu-Lin Tian, and Dan Wang, and Kun Zhu, and Qing-Gao Zhang, and Shuang-Ping Liu
February 2021, Burns : journal of the International Society for Burn Injuries,
Shu-Guang Du, and Hua-Min Zhang, and Yun-Xia Ji, and Yu-Lin Tian, and Dan Wang, and Kun Zhu, and Qing-Gao Zhang, and Shuang-Ping Liu
April 2020, European review for medical and pharmacological sciences,
Shu-Guang Du, and Hua-Min Zhang, and Yun-Xia Ji, and Yu-Lin Tian, and Dan Wang, and Kun Zhu, and Qing-Gao Zhang, and Shuang-Ping Liu
January 2018, European review for medical and pharmacological sciences,
Shu-Guang Du, and Hua-Min Zhang, and Yun-Xia Ji, and Yu-Lin Tian, and Dan Wang, and Kun Zhu, and Qing-Gao Zhang, and Shuang-Ping Liu
August 2020, European review for medical and pharmacological sciences,
Shu-Guang Du, and Hua-Min Zhang, and Yun-Xia Ji, and Yu-Lin Tian, and Dan Wang, and Kun Zhu, and Qing-Gao Zhang, and Shuang-Ping Liu
May 2019, Oncology reports,
Shu-Guang Du, and Hua-Min Zhang, and Yun-Xia Ji, and Yu-Lin Tian, and Dan Wang, and Kun Zhu, and Qing-Gao Zhang, and Shuang-Ping Liu
July 2022, Genes & genomics,
Shu-Guang Du, and Hua-Min Zhang, and Yun-Xia Ji, and Yu-Lin Tian, and Dan Wang, and Kun Zhu, and Qing-Gao Zhang, and Shuang-Ping Liu
January 2022, American journal of cancer research,
Shu-Guang Du, and Hua-Min Zhang, and Yun-Xia Ji, and Yu-Lin Tian, and Dan Wang, and Kun Zhu, and Qing-Gao Zhang, and Shuang-Ping Liu
January 2021, BioMed research international,
Shu-Guang Du, and Hua-Min Zhang, and Yun-Xia Ji, and Yu-Lin Tian, and Dan Wang, and Kun Zhu, and Qing-Gao Zhang, and Shuang-Ping Liu
January 2019, Oncology reports,
Shu-Guang Du, and Hua-Min Zhang, and Yun-Xia Ji, and Yu-Lin Tian, and Dan Wang, and Kun Zhu, and Qing-Gao Zhang, and Shuang-Ping Liu
January 2019, Molecular medicine reports,
Copied contents to your clipboard!